These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16375248)

  • 1. State of the art analytical comparability: a review.
    Chirino AJ; Mire-Sluis AR
    Dev Biol (Basel); 2005; 122():3-26. PubMed ID: 16375248
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative design for long-term stability testing of large molecules: a scientific discussion paper from an EBF Topic Team.
    Pihl S; Andersen L; Bruzelius K; Schiebl C; Golob M
    Bioanalysis; 2015 Dec; 7(24):3073-83. PubMed ID: 26626699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of biosimilar therapies--opportunities and obstacles. Commentary.
    Goldsmith D
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v1-3. PubMed ID: 16959788
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparability is not just analytical equivalence.
    Lubiniecki AS; Marcia Federici M
    Biologicals; 2006 Mar; 34(1):45-7. PubMed ID: 16330221
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.
    Carpenter JF; Randolph TW; Jiskoot W; Crommelin DJ; Middaugh CR; Winter G
    J Pharm Sci; 2010 May; 99(5):2200-8. PubMed ID: 19918982
    [No Abstract]   [Full Text] [Related]  

  • 7. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation.
    Timmerman P
    Bioanalysis; 2014 Mar; 6(5):599-604. PubMed ID: 24620801
    [No Abstract]   [Full Text] [Related]  

  • 8. [Problems in the production of pharmaceutical preparations].
    Dtsch Med J; 1972 Sep; 23(9):Suppl:XL. PubMed ID: 4640459
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of standard and state of the art analytical technology-bioassays.
    Indelicato SR; Bradshaw SL; Chapman JW; Weiner SH
    Dev Biol (Basel); 2005; 122():103-14. PubMed ID: 16375255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals.
    Srebalus Barnes CA; Lim A
    Mass Spectrom Rev; 2007; 26(3):370-88. PubMed ID: 17410555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro tomography and non-destructive imaging at depth of pharmaceutical solid dosage forms.
    Zeitler JA; Gladden LF
    Eur J Pharm Biopharm; 2009 Jan; 71(1):2-22. PubMed ID: 18778770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs in action.
    Eggert US; Superti-Furga G
    Nat Chem Biol; 2008 Jan; 4(1):7-11. PubMed ID: 18084271
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabonomics in pharmaceutical discovery and development.
    Robertson DG; Reily MD; Baker JD
    J Proteome Res; 2007 Feb; 6(2):526-39. PubMed ID: 17269709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulating drugs for effectiveness and safety: a public health perspective.
    Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J
    Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264
    [No Abstract]   [Full Text] [Related]  

  • 15. Introductory note to the three-part series of papers by Basant Sharma on: immunogenicity of therapeutic proteins: how to assess and the role of pharmaceutical quality.
    Trouvin JH
    Biotechnol Adv; 2007; 25(3):307-9. PubMed ID: 17321095
    [No Abstract]   [Full Text] [Related]  

  • 16. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of product comparability.
    Builder SE
    Dev Biol Stand; 1998; 96():83-90. PubMed ID: 9890520
    [No Abstract]   [Full Text] [Related]  

  • 18. Establishment of criteria for determining comparability of "well-characterized" proteins.
    Cavagnaro JA
    Dev Biol Stand; 1998; 96():79-81. PubMed ID: 9890519
    [No Abstract]   [Full Text] [Related]  

  • 19. Biological assay challenges from compound solubility: strategies for bioassay optimization.
    Di L; Kerns EH
    Drug Discov Today; 2006 May; 11(9-10):446-51. PubMed ID: 16635808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current problems in the quality controll of pharmaceutical preparations manufactured in pharmacies I. Identification tests].
    Horváth P; Elekné Vörös Z; Sinkó B; Vámos J; Takácsné Novák K
    Acta Pharm Hung; 2006; 76(2):86-94. PubMed ID: 17094667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.